Elite in Chondrosarcoma

Paolo G. Casali

Milan, IT 
Elite in Chondrosarcoma
Milan, IT 
OverviewLocationsClinical Research

Overview

Paolo Casali practices in Milan, Italy. Mr. Casali is rated as an Elite expert by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Myxoid Liposarcoma, Solitary Fibrous Tumor, Pancreaticoduodenectomy, and Hysterectomy.

His clinical research consists of co-authoring 284 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Chondrosarcoma.

Gender
Male

Locations

Milan, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment
A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
Enrollment Status: Completed
Publish Date: April 14, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

284 Total Publications

Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
Journal: JAMA oncology
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Casali's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 8 Distinguished Conditions
View All 7 Advanced Conditions
View All 25 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile